Opinion|Videos|June 1, 2026
Indirect Trial Comparisons in Metastatic Castration-Sensitive Prostate Cancer
Fact checked by: Tracy Ann Politowicz
This episode examines how indirect trial comparisons can help guide ARPI selection in metastatic castration-sensitive prostate cancer when head-to-head studies are unavailable, while emphasizing the importance of patient-specific factors, tolerability, and clinical judgment.
Episodes in this series
This episode examines how indirect trial comparisons can help guide the selection of an androgen receptor pathway inhibitor (ARPI) in metastatic castration-sensitive prostate cancer when head-to-head studies are unavailable, while emphasizing the importance of patient-specific factors, tolerability, and clinical judgment.
Related Content
Latest CME
Trending on Urology Times
1
The ArteraAI Prostate Test: What It Is and How It Works
2
HHS requests testosterone therapy label updates, citing new safety data
3
Retrospective study suggests differences in OAB therapy persistence among older adults
4
FDA gives nod to feasibility study of NanoKnife IRE for benign prostatic hyperplasia
5